Oxana Beskrovnaya PhD

Oxana is currently Chief Scientific Officer at Dyne Therapeutics where she leads preclinical research and development focused on receptor-mediated delivery of oligonucleotides for the treatment of muscle genetic diseases. An accomplished R&D leader with a track record of discovering and developing first-in-class therapeutics for rare genetic diseases, Oxana has worked across multiple disease indications in both large biopharmaceutical and small biotech companies.

Prior to joining Dyne, Oxana served as Head of Musculoskeletal and Renal Research at Sanofi. In that role, she was responsible for conducting research and advancing a pipeline of drug candidates using multiple therapeutic modalities including nucleic acids, proteins, and small molecules. Before that Oxana served in various capacities of increasing responsibility at Genzyme where she managed research in genetics, disease mechanisms, target discovery/validation, and translational biomarkers in rare renal, metabolic, skeletal, and neuromuscular diseases.

Oxana authored numerous patents, invited reviews, editorials, book chapters, and original research articles in major scientific journals including Nature, Nature Medicine, Cell, and Molecular Cell. Oxana received her doctorate in genetics from Moscow Genetics Institute followed by postdoctoral fellowship training in neuromuscular diseases with HHMI at the University of Iowa.